Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier...
Hence then, the article about adc therapeutics reports second quarter 2026 financial results and provides operational updates was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates )
Also on site :
- Box Office: ‘Digger’ Nosediving With $3.4 Million on Opening Day, ‘Verity’ Lands at No. 1 With $15.1 Million on Friday
- We Asked 3 Travel Advisors for Vermont’s Best Leaf-Peeping Trip for the Whole Family—They All Said the Same Thing
- Hallmark’s ‘Countdown to Christmas’ Started With Just 4 Movies—Here’s a Look Back at the Original Lineup